Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan

Patent No. EP2861210 (titled "Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan") was filed by Ipsen Biopharm on Jun 12, 2013. The application was issued on May 3, 2017.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
TEVA PHARMACEUTICALSFeb 5, 2018D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2861210

IPSEN BIOPHARM
Application Number
EP13731230A
Filing Date
Jun 12, 2013
Status
Revoked
May 20, 2022
Publication Date
May 3, 2017